Comparison of HIV-Infected and Noninfected Patients Undergoing Bariatric Surgery: The ObeVIH Study.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
received:
06
09
2021
accepted:
10
01
2022
pubmed:
22
2
2022
medline:
18
6
2022
entrez:
21
2
2022
Statut:
ppublish
Résumé
The aim of this study was to compare clinical characteristics and adipose/liver tissue histology analysis in HIV-infected and HIV-uninfected subjects undergoing bariatric surgery. This was a cross-sectional study of HIV-infected subjects undergoing single-port sleeve gastrectomy with prospective enrolment and frequency age (±5 years), sex, and body mass index (BMI, ± 5 kg/m2) matched on HIV-uninfected subjects. This study was conducted at a single clinical site at Pitié-Salpêtrière hospital-Paris-France comprising 19 HIV-uninfected and 21 HIV-infected subjects with plasma VL < 20 copies/mL, all with a BMI > 40 kg/m2 or >35 kg/m2 with comorbidities. Histology of subcutaneous and visceral abdominal adipose tissue (SCAT/VAT) and liver biopsies was collected during single-port sleeve gastrectomy. Outcomes included anthropometric characteristics, comorbidities, cardiovascular parameters, adipose tissue, and liver histology. The age of HIV-infected participants was (median, interquartile range IQR) 48 y (42-51), with 76.2% females, a BMI of 41.4 kg/m2 (37.3-44.4), an antiretroviral duration of 16 y (8-21), current integrase strand transfer inhibitor (INSTI)-based regimen in 15 participants and non-INSTI regimen in 6 participants, and a CD4 count of 864/mm3 (560-1066). The age of controls was 43 y (37-51), with 78.9% females and a BMI of 39.2 kg/m2 (36.3-42.6). Anthropometric characteristics, comorbidities, and cardiovascular parameters did not differ according to HIV status and INSTI treatment. The number of macrophage crown-like structures in SCAT was lower in INSTI-treated participants than in HIV-uninfected participants (P = 0.02) and non-INSTI-treated HIV-infected subjects (P = 0.07). Hepatic steatosis and liver disease severity global score were lower in INSTI-treated participants than in non-INSTI-treated HIV-infected participants (P = 0.05 and P = 0.04, respectively). HIV-infected and HIV-uninfected subjects undergoing bariatric surgery presented a similar profile regarding anthropometric measures, cardiovascular parameters, and comorbidities. However, INSTI-treated participants presented milder SCAT and liver alterations than non-INSTI-treated participants.
Identifiants
pubmed: 35185138
doi: 10.1097/QAI.0000000000002939
pii: 00126334-202206010-00017
doi:
Substances chimiques
HIV Integrase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
240-248Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
This study was funded in part by ANRS (ECTZ121032). V.P. reports lecture fees from Gilead, ViiV, MSD, Roche, Biogen, and Merck Serono outside the submitted work. J.C. reports grants paid to the institution from ViiV healthcare and MSD and lecture fees from Gilead, ViiV Healthcare, MSD, and Janssen outside the submitted work. C.L. reports lecture fees from MSD outside the submitted work. F.B. reports research grants from Amgen and lecture fees from Gilead, ViiV Healthcare, Amgen, Sanofi, MSD, and Servier outside the submitted work. M.C.B.R. reports lecture fees from Gilead and Mayoli-Spindler outside the submitted work. D.C. reports HIV grants from Janssen (2017–2018 and 2019–2020) and personal fees from Janssen (2018) and Gilead (2018 and 2020) for lectures on HIV outside the submitted work. The remaining authors have no funding or conflicts of interest to disclose.
Références
Gabuzda D, Jamieson BD, Collman RG, et al. Pathogenesis of aging and age-related comorbidities in people with HIV: highlights from the HIV ACTION workshop. Pathog Immun. 2020;5:143–174.
Debroy P, Sim M, Erlandson KM, et al. Progressive increases in fat mass occur in adults living with HIV on antiretroviral therapy, but patterns differ by sex and anatomic depot. J Antimicrob Chemother. 2019;74:1028–1034.
Godfrey C, Bremer A, Alba D, et al. Obesity and fat metabolism in human immunodeficiency virus-infected individuals: immunopathogenic mechanisms and clinical implications. J Infect Dis. 2019;220:420–431.
WHO. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva, Switzerland: Organization WHO; 2000.
Pourcher G, Costagliola D, Martinez V. Obesity in HIV-infected patients in France: prevalence and surgical treatment options. J Visc Surg. 2015;152:33–37.
Ghosn J, Abdoul H, Fellahi S, et al. Prevalence of silent atherosclerosis and other comorbidities in an outpatient cohort of adults living with HIV: associations with HIV parameters and biomarkers. AIDS Res Hum Retroviruses. 2021;37:101–108.
Hanttu A, Kauppinen KJ, Kivela P, et al. Prevalence of obesity and disturbances in glucose homeostasis in HIV-infected subjects and general population—missed diagnoses of diabetes? HIV Med. 2021;22:244–253.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376:641–651.
Gronroos S, Helmio M, Juuti A, et al. Effect of laparoscopic sleeve gastrectomy vs roux-en-Y gastric bypass on weight loss and quality of life at 7 years in patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2021;156:137–146.
Pourcher G, Di Giuro G, Lafosse T, et al. Routine single-port sleeve gastrectomy: a study of 60 consecutive patients. Surg Obes Relat Dis. 2013;9:385–389.
Pourcher G, Peytavin G, Schneider L, et al. Bariatric surgery in HIV patients: experience of an obesity reference center in France. Surg Obes Relat Dis. 2017;13:1990–1996.
Flancbaum L, Drake V, Colarusso T, et al. Initial experience with bariatric surgery in asymptomatic human immunodeficiency virus-infected patients. Surg Obes Relat Dis. 2005;1:73–76.
Fysekidis M, Cohen R, Bekheit M, et al. Sleeve gastrectomy is a safe and efficient procedure in HIV patients with morbid obesity: a case series with results in weight loss, comorbidity evolution, CD4 count, and viral load. Obes Surg. 2015;25:229–233.
Koethe JR, Lagathu C, Lake JE, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6:48.
Erlandson KM, Carter CC, Melbourne K, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73:1440–1451.
Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis. 2020;71:e471–e477.
Assoumou L, Racine C, Fellahi S, et al. Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine. AIDS. 2020;34:1859–1862.
Gorwood J, Bourgeois C, Pourcher V, et al. The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes. Clin Infect Dis. 2020;71:e549–e560.
Bohdjalian A, Langer FB, Shakeri-Leidenmuhler S, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20:535–540.
Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367.
de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251–1260.
Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79–108.
Bruce RA, Lovejoy FW Jr, Pearson R, et al. Normal respiratory and circulatory pathways of adaptation in exercise. J Clin Invest. 1949;28:1423–1430.
Srinivasa S, Torriani M, Fitch KV, et al. Brief report: adipogenic expression of Brown fat genes in HIV and HIV-related parameters. J Acquir Immune Defic Syndr. 2019;82:491–495.
Schepis T, Gaemperli O, Koepfli P, et al. Added value of coronary artery calcium score as an adjunct to gated SPECT for the evaluation of coronary artery disease in an intermediate-risk population. J Nucl Med. 2007;48:1424–1430.
Fadhl H, Suhool A, Donatelli G, et al. Umbilical single-port sleeve gastrectomy as a standardized procedure: how to do it? (Video). Obes Surg. 2019;29:1697–1698.
Frosio F, Suhool A, Ferraz JM, et al. Anatomical quality criteria for sleeve gastrectomy. Obes Surg. 2021;31:1541–1548.
Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–1759.
Talalaj M, Bogolowska-Stieblich A, Wasowski M, et al. The influence of laparoscopic sleeve gastrectomy on body composition and fat distribution in obese caucasian men and women. Obes Surg. 2020;30:3974–3981.
Wrzosek M, Wisniewska K, Sawicka A, et al. Early onset of obesity and adult onset of obesity as factors affecting patient characteristics prior to bariatric surgery. Obes Surg. 2018;28:3902–3909.
Forrester JE, Sheehan HM, Joffe TH. A validation study of body composition by bioelectrical impedance analysis in human immunodeficiency virus (HIV)-positive and HIV-negative hispanic men and women. J Am Diet Assoc. 2008;108:534–538.
Boccara F, Lang S, Meuleman C, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013;61:511–523.
Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381:803–815.
Bastard JP, Pelloux V, Alili R, et al. Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir/maraviroc. AIDS. 2021;35:1625–1630.
Cimini FA, Barchetta I, Ciccarelli G, et al. Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. Diabetes Metab Res Rev. 2021;37:e3358.
Divoux A, Tordjman J, Lacasa D, et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes. 2010;59:2817–2825.
Kirkegaard-Klitbo DM, Thomsen MT, Gelpi M, et al. Hepatic steatosis associated with exposure to elvitegravir and raltegravir. Clin Infect Dis. 2021;73:e811–e814.